84211-30-3

Basic information

• Product Name: 3,4-Dihydroxy-5-Nitrobenzoic Acid
• Synonyms: 3,4-Dihydroxy-5-Nitrobenzoic Acid;Benzoic acid, 3,4-dihydroxy-5-nitro-
• CAS NO: 84211-30-3
• Molecular Formula: C₇H₅NO₆
• Molecular Weight: 199.12
• Mol File: 84211-30-3.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 411.1°C at 760 mmHg
• Flash Point: 188°C
• Appearance: /
• Density: 1.799g/cm³
• Vapor Pressure: 1.7E-07mmHg at 25°C
• Refractive Index: 1.715
• Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• Solubility: DMSO (Slightly), Methanol (Slightly)
• CAS DataBase Reference: 3,4-Dihydroxy-5-Nitrobenzoic Acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-Dihydroxy-5-Nitrobenzoic Acid(84211-30-3)
• EPA Substance Registry System: 3,4-Dihydroxy-5-Nitrobenzoic Acid(84211-30-3)

Safety Data

• Hazardous Substances Data: 84211-30-3(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 84211-30-3 differently. You can refer to the following data:
1. 3,4-Dihydroxy-5-nitrobenzoic Acid is a useful synthetic intermediate in the synthesis of Entacapone; a peripherally selective inhibitor of catechol-O-methyltransferase (COMT). Also an antiparkinsonian.
2. 3,4-Dihydroxy-5-nitrobenzoic Acid is a useful synthetic intermediate in the synthesis of Entacapone (E558500); a peripherally selective inhibitor of catechol-O-methyltransferase (COMT). Also an antiparkinsonian.

InChI:InChI=1/C7H5NO6/c9-5-2-3(7(11)12)1-4(6(5)10)8(13)14/h1-2,9-10H,(H,11,12)

Upstream product

• 116313-85-0 3,4-dihydroxy-5-nitrobenzaldehyde 
• 42590-00-1 4-hydroxy-3-methoxy-5-nitrobenzoic acid methyl ester 
• 3943-74-6 4-hydroxy-3-methoxybenzoic acid methyl ester 
• 15785-54-3 5-nitrovanillic acid 

Downstream Products

• 125629-02-9 butyl 3,4-dihydroxy-5-nitrobenzoate 
• 148546-85-4 methyl 3-amino-4,5-dimethoxybenzoate 
• 148546-84-3 methyl 3,4-dimethoxy-5-nitrobenzoate 
• 84211-27-8 3-amino-4,5-dihydroxybenzoic acid 
• 125629-01-8 methyl 3,4-dihydroxy-5-nitro-benzoate 
• 116314-97-7 3,4-diacetoxy-5-nitrobenzoic acid 
• 119734-29-1 (6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-1-carboxy-1-methyl-ethoxyimino]-acetylamino}-3-{[(3,4-dihydroxy-5-nitro-benzoyl)-ethyl-amino]-methyl}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 
• 119734-80-4 (6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-1-carboxy-1-methyl-ethoxyimino]-acetylamino}-3-[(3,4-dihydroxy-5-nitro-benzoylamino)-methyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 
• 119734-76-8 (6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-ethoxyimino]-acetylamino}-3-[(3,4-dihydroxy-5-nitro-benzoylamino)-methyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 
• 112057-05-3 3,4-diacetoxy-5-nitrobenzoyl chloride 

Relevant articles and documents

Synthesis of proposed structure of aaptoline a, a marine sponge-derived 7,8-dihydroxyquinoline, and its neuroprotective properties in c. Elegans

A concise and efficient synthesis of the proposed structure of aaptoline A, a 7,8-dihy-droxyquinoline derived from a marine sponge, was accomplished in seven steps with a 52% overall yield. A key feature of the synthesis is the high-yielding Ag(I)-catalyz

Design and structural analysis of aromatic inhibitors of type II dehydroquinase from mycobacterium tuberculosis

3-Dehydroquinase, the third enzyme in the shikimate pathway, is a potential target for drugs against tuberculosis. Whilst a number of potent inhibitors of the Mycobacterium tuberculosis enzyme based on a 3-dehydroquinate core have been identified, they generally show little or no in vivo activity, and were synthetically complex to prepare. This report describes studies to develop tractable and drug-like aromatic analogues of the most potent inhibitors. A range of carbon-carbon linked biaryl analogues were prepared to investigate the effect of hydrogen bond acceptor and donor patterns on inhibition. These exhibited inhibitory activity in the high-micromolar range. The addition of flexible linkers in the compounds led to the identification of more potent 3-nitrobenzylgallate- and 5-aminoiso-phthalate-based analogues.

Discovery of a long-acting, peripherally selective inhibitor of catechol- O -methyltransferase

Novel nitrocatechol-substituted heterocycles were designed and evaluated for their ability to inhibit catechol-O-methyltransferase (COMT). Replacement of the pyrazole core of the initial hit 4 with a 1,2,4-oxadiazole ring resulted in a series of compounds endowed with longer duration of COMT inhibition. Incorporation of a pyridine N-oxide residue at position 3 of the 1,2,4-oxadiazole ring led to analogue 37f, which was found to possess activity comparable to entacapone and lower toxicity in comparison to tolcapone. Lead structure 37f was systematically modified in order to improve selectivity and duration of COMT inhibition as well as to minimize toxicity. Oxadiazole 37d (2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4, 6-dimethylpyridine 1-oxide (BIA 9-1067)) was identified as a long-acting, purely peripheral inhibitor, which is currently under clinical evaluation as an adjunct to l-Dopa therapy of Parkinson's disease.